Today’s News Headlines

GLP-1 medications remain the biggest story in obesity medicine, but the conversation is shifting from
“who can get them?” to “how do we use them well?” Newer research is continuing to refine expectations
around weight loss, muscle preservation, and long-term maintenance, while FDA and industry updates
keep the access and safety picture moving.
(fda.gov)

Today’s Top Stories

1) FDA warns about unapproved GLP-1 products as demand stays high

The FDA says it continues to see safety concerns tied to unapproved semaglutide and tirzepatide
products, including compounded versions and counterfeit drugs. The agency has also received reports
suggesting some patients may have been prescribed doses beyond what is listed on the FDA-approved label.
(fda.gov)

Why it matters: When people are eager for weight loss, the gray market can look tempting — but product quality and dosing safety matter as much as the medication itself. (fda.gov)

Source: FDA warning on unapproved GLP-1 drugs. (fda.gov)

2) New research suggests GLP-1s don’t cause the extreme muscle loss some people fear

A 2026 proof-of-concept clinical trial and related preclinical work found that GLP-1 medicines primarily
reduced body fat, with only a small decrease in lean body mass rather than the dramatic muscle loss
seen in social media claims. That doesn’t mean muscle maintenance is automatic — but it does mean
the “all the weight comes from muscle” narrative is overstated.
(pubmed.ncbi.nlm.nih.gov)

Why it matters: This is a useful reminder to pair medication with protein, resistance training, and adequate food intake instead of panic. (pubmed.ncbi.nlm.nih.gov)

Source: PubMed study on body composition with GLP-1 medicines. (pubmed.ncbi.nlm.nih.gov)

3) Drugmakers are still cutting net prices on popular obesity meds

STAT reports that Novo Nordisk and Eli Lilly have been lowering net prices for GLP-1 weight-loss drugs
through discounts and broader access deals, including recent pricing moves tied to government and insurer
negotiations. That may improve affordability for some patients, though retail sticker prices and insurance rules
remain major barriers.
(statnews.com)

Why it matters: Cost is still one of the biggest reasons people stop treatment, skip doses, or never start at all. (statnews.com)

Source: STAT on GLP-1 pricing changes. (statnews.com)

4) Exercise may amplify the health benefits of medication-based weight loss

A randomized trial found that combining exercise with GLP-1 receptor agonist treatment reduced abdominal obesity
and inflammation more than either approach alone in the study setting. The takeaway is not “meds versus lifestyle” —
it’s that the best outcomes often come from both.
(pubmed.ncbi.nlm.nih.gov)

Why it matters: Sustainable weight loss is rarely one intervention; it’s a system of habits and tools working together.
(pubmed.ncbi.nlm.nih.gov)

Source: PubMed randomized controlled trial. (pubmed.ncbi.nlm.nih.gov)

Deep Dive: Medication Monday

GLP-1s are powerful, but they’re not magic — and that’s good news

Today’s most important medication lesson is simple: GLP-1s such as semaglutide and tirzepatide are FDA-approved
for specific weight-management indications, and they work best as part of a long-term plan that includes nutrition,
movement, sleep, and follow-up care. FDA labeling and agency materials continue to emphasize approved use, dose
escalation, and the need to watch for common side effects like nausea and gastrointestinal symptoms.
(fda.gov)

A practical myth-buster: the goal is not to “eat as little as possible” on GLP-1s. That can backfire by worsening
fatigue, lean mass loss risk, and rebound hunger. Instead, prioritize protein at each meal, keep strength training
on the calendar, and treat medication as appetite support — not a substitute for basic nourishment.
(pubmed.ncbi.nlm.nih.gov)

Cost-saving strategies to know:

• Ask your clinician whether your diagnosis and insurance plan support coverage for an FDA-approved obesity indication.
  (fda.gov)
• If a brand-name drug is unaffordable, ask about manufacturer savings programs, prior authorization help, and pharmacy benefit exceptions.
  Pricing and access are changing, but not evenly.
  (statnews.com)
• Be cautious with compounded or unapproved products; the FDA has specifically warned about quality and dosing concerns.
  (fda.gov)

Quick Hits

• The FDA continues to monitor semaglutide-related safety issues and counterfeit products.
  (fda.gov)
• New research is pushing back on exaggerated claims about muscle loss during GLP-1 treatment.
  (pubmed.ncbi.nlm.nih.gov)
• Exercise plus medication remains a strong combo for body composition and inflammation markers.
  (pubmed.ncbi.nlm.nih.gov)
• Drug pricing pressure is finally producing some access movement, though the benefits are uneven.
  (statnews.com)
• FDA-approved labels still emphasize that these medications are adjuncts to diet and physical activity, not replacements for them.
  (fda.gov)
• Patients should not assume a social-media source is safe or medically accurate just because it sounds experiential or “natural.”
  (fda.gov)

By The Numbers

5% to 10% of body weight loss has been associated with reduced cardiovascular risk in adults with obesity or overweight,
according to FDA materials. That’s a meaningful reminder that you do not need extreme, rapid loss for real health benefits.
(fda.gov)

Why readers should care: Modest, sustained progress can improve health even when the scale moves slowly.
(fda.gov)

Source: FDA approval announcement for Zepbound.
(fda.gov)

Ask The Community

What has helped you most this month: medication, meal planning, strength training, better sleep, or simply being more consistent?

Tomorrow’s Preview

Tomorrow we break down one recent obesity study in plain English and separate what the research actually showed from the headlines people are sharing online.